Suppr超能文献

转移性膀胱癌患者化疗治疗中的社会人口学差异及其对生存的影响。

Sociodemographic disparities in chemotherapy treatment and impact on survival among patients with metastatic bladder cancer.

作者信息

Klapheke Amy, Yap Stanley A, Pan Kevin, Cress Rosemary D

机构信息

Public Health Institute, Cancer Registry of Greater California, Sacramento, CA; Department of Public Health Sciences, University of California Davis, Davis, CA.

Department of Urology, University of California Davis, Sacramento, CA; University of California Davis Comprehensive Cancer Center, Sacramento, CA.

出版信息

Urol Oncol. 2018 Jun;36(6):308.e19-308.e25. doi: 10.1016/j.urolonc.2018.03.008. Epub 2018 Apr 5.

Abstract

OBJECTIVE

To evaluate how socioeconomic status and other demographic factors are associated with the receipt of chemotherapy and subsequent survival in patients diagnosed with metastatic bladder cancer.

METHODS

Using data from the California Cancer Registry, we identified 3,667 patients diagnosed with metastatic urothelial carcinoma of the urinary bladder between 1988 and 2014. The characteristics of patients who did and did not receive chemotherapy as part of the first course of treatment were compared using chi-square tests. Logistic regression was used to identify predictors of chemotherapy treatment. Fine and Gray competing-risks regression and Cox proportional hazards regression were used to estimate bladder cancer-specific and all-cause mortality, respectively.

RESULTS

Less than half (46.3%) of patients received chemotherapy. Patients from the lowest socioeconomic quintile were half as likely to have chemotherapy as those from highest quintile (odds ratio = 0.5, 95% CI: 0.4, 0.7). Unmarried patients were significantly less likely to receive treatment (odds ratio = 0.6, 95% CI: 0.5, 0.7). Not receiving chemotherapy was associated with greater mortality from bladder cancer (subdistribution hazard ratio = 1.4, 95% CI: 1.3, 1.5) and from all causes (hazard ratio = 2.0, 95% CI: 1.8, 2.1).

CONCLUSIONS

We found clear disparities in chemotherapy treatment and survival with respect to socioeconomic and marital status. Future studies should explore the possible reasons why patients with low socioeconomic status and who are unmarried are less likely to have chemotherapy.

摘要

目的

评估社会经济地位和其他人口统计学因素与转移性膀胱癌患者接受化疗及后续生存情况之间的关联。

方法

利用加利福尼亚癌症登记处的数据,我们确定了1988年至2014年间被诊断为转移性膀胱尿路上皮癌的3667例患者。使用卡方检验比较了接受和未接受化疗作为第一疗程治疗一部分的患者特征。采用逻辑回归来确定化疗治疗的预测因素。分别使用Fine和Gray竞争风险回归以及Cox比例风险回归来估计膀胱癌特异性死亡率和全因死亡率。

结果

不到一半(46.3%)的患者接受了化疗。社会经济地位最低五分位数的患者接受化疗的可能性仅为最高五分位数患者的一半(优势比 = 0.5,95%置信区间:0.4,0.7)。未婚患者接受治疗的可能性显著较低(优势比 = 0.6,95%置信区间:0.5,0.7)。未接受化疗与膀胱癌更高的死亡率(亚分布风险比 =

相似文献

引用本文的文献

9
Gender dimorphism in survival of patients with lymph node metastasis of bladder cancer.膀胱癌淋巴结转移患者生存中的性别二态性。
Ther Adv Med Oncol. 2022 Jun 28;14:17588359221108690. doi: 10.1177/17588359221108690. eCollection 2022.

本文引用的文献

1
Cancer statistics, 2018.癌症统计数据,2018 年。
CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4.
3
Urothelial carcinoma management in elderly or unfit patients.老年或身体状况不佳患者的尿路上皮癌管理
EJC Suppl. 2016 Mar;14(1):1-20. doi: 10.1016/j.ejcsup.2016.01.001. Epub 2016 Mar 22.
6
Epidemiology and risk factors of urothelial bladder cancer.尿路上皮膀胱癌的流行病学和危险因素。
Eur Urol. 2013 Feb;63(2):234-41. doi: 10.1016/j.eururo.2012.07.033. Epub 2012 Jul 25.
7
Contemporary management of muscle-invasive bladder cancer.肌层浸润性膀胱癌的当代治疗方法。
Expert Rev Anticancer Ther. 2012 Jul;12(7):941-50. doi: 10.1586/era.12.60.
8
The use and interpretation of competing risks regression models.竞争风险回归模型的使用和解释。
Clin Cancer Res. 2012 Apr 15;18(8):2301-8. doi: 10.1158/1078-0432.CCR-11-2097. Epub 2012 Jan 26.
9
Metastatic bladder cancer: a review of current management.转移性膀胱癌:当前治疗方法综述
ISRN Urol. 2011;2011:545241. doi: 10.5402/2011/545241. Epub 2011 Jun 9.
10
Ethnic differences in bladder cancer survival.膀胱癌生存的种族差异。
Urology. 2011 Sep;78(3):544-9. doi: 10.1016/j.urology.2011.02.042. Epub 2011 Jul 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验